The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory
response to various stimuli in humans and espacially during sepsis. Purpose of this phase I
clinical trial in healthy human males is to investigate various parameters concerning safety
and tolerability of CaCP29 and assess pharmacokinetic and pharmacodynamic parameters.